Loading...

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

PURPOSE: AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AZD1775 as monotherapy or in combination with chemothera...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Leijen, Suzanne, van Geel, Robin M.J.M., Pavlick, Anna C., Tibes, Raoul, Rosen, Lee, Razak, Albiruni R. Abdul, Lam, Raymond, Demuth, Tim, Rose, Shelonitda, Lee, Mark A., Freshwater, Tomoko, Shumway, Stuart, Liang, Li Wen, Oza, Amit M., Schellens, Jan H.M., Shapiro, Geoffrey I.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2016
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7845944/
https://ncbi.nlm.nih.gov/pubmed/27601554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.5991
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!